1-(环己基甲基)吡咯烷-2-酮 | 154349-85-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 1-(环己基甲基)吡咯烷-2-酮
• 英文名称: N-cyclohexylmethyl-2-pyrrolidone
• 英文别名: N-(cyclohexylmethyl)pyrrolidone；NCMeP；2-Pyrrolidinone, 1-(cyclohexylmethyl)-；1-(cyclohexylmethyl)pyrrolidin-2-one
• CAS: 154349-85-6
• 化学式: C₁₁H₁₉NO
• 分子量: 181.278
• InChiKey: IESLDMNLOWUVKI-UHFFFAOYSA-N

物化性质

• 沸点：
  313.6±11.0 °C(Predicted)
• 密度：
  1.027±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  20.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  uranyl nirate hexahydrate 、 1-(环己基甲基)吡咯烷-2-酮 以 乙醇 为溶剂， 生成 UO₂(nitrato)2(N-cyclohexylmethyl-2-pyrrolidone)2
  参考文献：
  名称：

  A structural study on uranyl (VI) nitrate complexes with cyclic amides: N-n-butyl-2-pyrrolidone, N-cyclohexylmethyl-2-pyrrolidone, and 1,3-dimethyl-2-imidazolidone

  摘要：

  Structural analyses Of UO2(NO3)(2)L-2 [L = N-n-butyl-2-pyrrolidone (NBP), N-cyclohexylmethyl-2-pyrrolidone (NCMeP), and 1,3dimethyl-2-imidazolidone (DMI)] have been carried out using X-ray diffraction method. These uranyl complexes were found to have a hexagonal bipyramidal structure. The bond distances (angstrom) of U=O and U-O(ligand), and bond angles (degrees) of U-O-C(carbonyl) are determined as follows: 1.774(2), 2.374(2), and 137.6(2) for UO2(NO3)(2)(NBP)(2); 1.770(l), 2.383(2), and 135.3(l) for UO2(NO3)(2)(NCMeP)(2); 1.771(2), 2.361(2), and 143.3(2) for UO2(NO3)(2)(DMI)(2)- In uranyl nitrate complexes with cyclic amides such as 2-pyrrolidone, urea, and caprolactam derivatives, a linear correlation was found to hold between U-O(ligand) bond distances and U O-C(carbonyl) bond angles. Vibrational frequencies Of UO2(NO3)(2)L-2 have also been measured by IR and Raman spectrophotometers. Using relationships between vibrational frequencies of O=U=O bonds and donor numbers (DNs) of ligands, it was found that donicities of N-substituted2-pyrrolidones (Me, Et, Bu, cyclohexyl, and cyclohexylmethyl) are in the range of 26-29, and the DN of 1,3-dimethyl-2-imidazolidone was estimated as 27.8. (c) 2005 Elsevier B.V. All rights reserved.

  DOI：

  10.1016/j.ica.2004.12.036
• 作为产物：
  描述：

  一氧化碳 、 (3-Chloro-propyl)-[1-cyclohexyl-meth-(E)-ylidene]-amine 在 偶氮二异丁腈 、 三正丁基氢锡 作用下， 以 苯 为溶剂， 80.0 ℃ 、9.12 MPa 条件下， 以61%的产率得到1-(环己基甲基)吡咯烷-2-酮
  参考文献：
  名称：

  Nitrogen-philic Cyclization of Acyl Radicals onto NC Bond. New Synthesis of 2-Pyrrolidinones by Radical Carbonylation/Annulation Method

  摘要：

  DOI：

  10.1021/ja980731n

文献信息

• A Multiphase Protocol for Selective Hydrogenation and Reductive Amination of Levulinic Acid with Integrated Catalyst Recovery
  作者：Alessandro Bellè、Tommaso Tabanelli、Giulia Fiorani、Alvise Perosa、Fabrizio Cavani、Maurizio Selva

  DOI：10.1002/cssc.201900925

  日期：2019.7.19

  reactions of levulinic acid (LA), hydrogenation and reductive amination with cyclohexylamine, were explored in a multiphase system composed of an aqueous solution of reactants, a hydrocarbon, and commercial 5 % Ru/C as a heterogeneous catalyst. By tuning the relative volume of the immiscible water/hydrocarbon phases and the concentration of the aqueous solution, a quantitative conversion of LA was achieved

  在60–150°C和15–35 bar H 2的条件下，在由反应物，碳氢化合物和商业化的水溶液组成的多相体系中，探索了乙酰丙酸（LA）的两个模型反应，氢化反应和环己胺的胺化反应。 5％Ru / C作为非均相催化剂。通过调节不混溶的水/烃相的相对体积和水溶液的浓度，通过形成γ-戊内酯或N可以实现LA的定量转化-（环己基甲基）吡咯烷酮的选择性分别> 95和88％。此外，催化剂可以分离在烃相中，并以有效的半连续方案进行再循环。在这种条件下，甲酸添加剂通过在催化剂表面的竞争性吸附影响了LA的反应性。该效果对于提高还原胺化过程的选择性至关重要。5％Ru / C与一系列碳载体的比较表明，以前从未报道过的烃相中的偏析现象是pH依赖性的，并且对于显示中等表面酸度的样品有效。
• Prophylactic/Therapeutic Agent for Diabetes
  申请人：Cho Nobuo

  公开号：US20090264650A1

  公开（公告）日：2009-10-22

  The present invention relates to a 11β-hydroxysteroid dehydrogenase 1 inhibitor comprising a compound represented by the formula (1): wherein each symbol is as defined in the description, or a salt thereof, or a prodrug thereof. The 11β-hydroxysteroid dehydrogenase 1 inhibitor of the present invention has a superior activity, and is useful as a pharmaceutical agent such as agents for the prophylaxis or treatment of diabetes, insulin resistance, obesity, abnormal lipid metabolism, hypertension and the like, and the like.

  本发明涉及一种11β-羟基类固醇脱氢酶1抑制剂，其包括由式（1）表示的化合物，其中每个符号如描述中所定义的，或其盐或前药。本发明的11β-羟基类固醇脱氢酶1抑制剂具有优异的活性，可用作药物剂，如用于预防或治疗糖尿病、胰岛素抵抗、肥胖症、异常脂质代谢、高血压等的药剂。
• PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1864971A1

  公开（公告）日：2007-12-12

  The present invention relates to a 11β-hydroxysteroid dehydrogenase 1 inhibitor comprising a compound represented by the formula (1): wherein each symbol is as defined in the description, or a salt thereof, or a prodrug thereof. The 11β-hydroxysteroid dehydrogenase 1 inhibitor of the present invention has a superior activity, and is useful as a pharmaceutical agent such as agents for the prophylaxis or treatment of diabetes, insulin resistance, obesity, abnormal lipid metabolism, hypertension and the like, and the like.

  本发明涉及一种 11β-羟基类固醇脱氢酶 1 抑制剂，由式（1）代表的化合物组成： 其中各符号如说明中所定义，或其盐，或其原药。本发明的11β-羟类固醇脱氢酶1抑制剂具有优异的活性，可作为药物制剂，如用于预防或治疗糖尿病、胰岛素抵抗、肥胖、脂代谢异常、高血压等疾病的药物。
• C5AR ANTAGONISTS
  申请人：ChemoCentryx, Inc.

  公开号：EP2381778B1

  公开（公告）日：2016-06-08